Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis

2018 ◽  
Vol 50 (5) ◽  
pp. 302
Author(s):  
Jane R. von Gaudecker
Keyword(s):  
Multiple Sclerosis ◽  
Factors Affecting ◽  
Disease Modifying Therapy ◽  
Disease Modifying

scholarly journals Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis

2018 ◽  
Vol 20 (6) ◽  
pp. 251-259 ◽  
Author(s):  
Andrew V. Thach ◽  
Carolyn M. Brown ◽  
Vivian Herrera ◽  
Rahul Sasane ◽  
Jamie C. Barner ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Satisfaction ◽  
Future Research ◽  
Research Committee ◽  
Medication Beliefs ◽  
Factors Affecting ◽  
The North ◽  
Disease Modifying Therapy ◽  
Effective Interventions ◽  
Disease Modifying

Abstract Background: Adherence to disease-modifying therapy (DMT) remains problematic for many patients with multiple sclerosis (MS). An improved understanding of factors affecting DMT adherence may inform effective interventions. This study examined associations between treatment satisfaction, medication beliefs, and DMT adherence. Methods: A survey was mailed in 2016 to 600 adult patients with relapsing-remitting MS taking an injectable or oral DMT. Patients were sampled from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. The survey measured self-reported DMT adherence (doses taken divided by doses prescribed during previous 2-week period—adherence ≥0.80), DMT satisfaction using the Treatment Satisfaction Questionnaire for Medication version II, medication beliefs using the Beliefs About Medicines Questionnaire, and demographic and clinical covariates. Relationships between variables were examined using multivariate logistic regression. Results: Final analyses included 489 usable surveys. Mean ± SD participant age was 60.5 ± 8.3 years. Most respondents were white (93.8%), female (86.6%), taking an injectable DMT (66.9%), and adherent to DMT (92.8%). Significant predictors of DMT adherence were age (odds ratio [OR], 1.086; 95% CI, 1.020–1.158; P = .011), type of DMT (oral vs. injectable; OR, 23.350; 95% CI, 2.254–241.892; P = .008), and DMT experience (naive vs. experienced; OR, 2.831; 95% CI, 1.018–7.878; P = .046). Conclusions: In patients with MS sampled from a patient registry, treatment satisfaction and medication beliefs were not significantly associated with DMT adherence. Based on significant predictors, younger patients, patients taking injectable DMTs, and patients with previous experience with another DMT(s) are at higher risk for nonadherence. Future research is warranted to assess relationships between variables in more diverse MS populations.

scholarly journals Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis

Neurology ◽  
2016 ◽  
Vol 86 (14) ◽  
pp. 1287-1295 ◽  
Author(s):  
Tingting Zhang ◽  
Helen Tremlett ◽  
Stella Leung ◽  
Feng Zhu ◽  
Elaine Kingwell ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying Therapy ◽  
Disease Modifying

Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy

2009 ◽  
Vol 41 (2) ◽  
pp. 119-123 ◽  
Author(s):  
Jennifer E. Thannhauser ◽  
Jean K. Mah ◽  
Luanne M. Metz
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying Therapy ◽  
Multiple Sclerosis Disease ◽  
Disease Modifying

scholarly journals Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis

2017 ◽  
Vol 19 (1) ◽  
pp. 11-14 ◽  
Author(s):  
Gary Birnbaum
Keyword(s):  
Multiple Sclerosis ◽  
Acute Disease ◽  
Published Data ◽  
Secondary Progressive ◽  
Disease Modifying Therapy ◽  
Scale Scores ◽  
Group A ◽  
Multiple Variables ◽  
Disease Modifying ◽  
Group B

Background: Current disease-modifying therapies (DMTs) are of benefit only in people with relapsing forms of multiple sclerosis (RMS). Thus, safely stopping DMTs in people with secondary progressive MS may be possible. Methods: Two groups of patients with MS were studied. Group A consisted of 77 patients with secondary progressive MS and no evidence of acute central nervous system inflammation for 2 to 20 years. These patients were advised to stop DMTs. Group B consisted of 17 individuals with RMS who stopped DMTs on their own. Both groups were evaluated at treatment cessation and for a minimum of 1 year thereafter. Multiple variables were assessed to determine those that predicted recurrent acute disease. Results: Nine patients in group A (11.7%) and ten patients in group B (58.8%) had recurrent acute disease, almost always within 1 to 2 years of stopping treatment. The only variable of significance in group A distinguishing stable and relapsing patients was age (P = .0003), with relapsing patients being younger. Group B patients were younger and had significantly lower Expanded Disability Status Scale scores than group A, with no significant differences in age between relapsed and stable patients. Conclusions: The DMTs can be stopped safely in older patients with MS (≥7 decades) with no evidence of acute disease for 2 years or longer, with an almost 90% probability of remaining free of acute recurrence. The high proportion of untreated patients with RMS experiencing recurrent acute disease is consistent with published data.

Sign in / Sign up

Export Citation Format

Share Document